Allyson Maur is speaking on the panel “Compounding Interest: Accumulating Insight into Recent Advertising and Promotion Trends in Compounding” at the Food & Drug Law Institute Advertising & Promotion for Medical Products Conference on October 15.
This panel will explore key developments around drug compounding that are shaping the pharmaceutical industry. Current issues will be discussed, with a focus on relevant Lanham Act litigation as a prevalent example of recent trends, and advertising by 503A and 503B pharmacies more broadly.
For additional details and registration, please visit the event website.